共 57 条
[1]
Feigin VL(2019)Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 18 459-480
[2]
Nichols E(2021)Burden of Neurological Disorders Across the US From 1990–2017 JAMA Neurol 78 165-335
[3]
Alam T(2018)The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy NeuroRx 15 324-103
[4]
Feigin VL(2020)Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide J Pharmacol Exp Ther 374 93-e1377
[5]
Vos T(2020)Efficacy and safety of eptinezumab in patients with chronic migraine Neurology 94 e1365-254
[6]
Alahdab F(2020)Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) Cephalalgia 40 241-832
[7]
Raffaelli B(2018)Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults Cephalalgia 38 815-11
[8]
Reuter U(2021)Shift from high-frequency to low-frequency episodic migraine in patients treated with galcanezumab: results from two global randomized clinical trials J Headache Pain 22 48-8
[9]
Garcia-Martinez LF(2019)Galcanezumab in episodic migraine: Subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) J Headache Pain 20 1-14
[10]
Raport CJ(2022)Task-switching abilities in episodic and chronic migraine Neurol Sci 2021 1-549